Clinical Trials

460 enrolled

Ovarian Cancer Recurrent

NCT07061977 2026-05-26

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT01174121 2026-05-22

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer

BreastGastrointestinalGynecologic

332 enrolled

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06952504 2026-05-22

TroFuse-033

1,123 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT07216703 2026-05-22

TroFuse-036

1,023 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

NCT03144466 2026-05-20

PAPAYA

Phase 1 Terminated

1 enrolled 7 charts

Uterine Cervical Neoplasms

NCT03430700 2026-05-20

PROMPT

Phase 2 Completed

20 enrolled 10 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05761951 2026-05-19

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

8 enrolled

Phase 3 Not yet recruiting

Endometrial Neoplasms

NCT07578649 2026-05-19

Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer

600 enrolled

Endometrial Neoplasms

NCT06083844 2026-05-18

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy

20 enrolled

Ovarian Neoplasms

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

46 enrolled

Endometrial Neoplasms

NCT04977453 2026-05-15

Keynote B59

Phase 1 Active not recruiting

317 enrolled

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT02298959 2026-05-13

Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer

59 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicSarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 Completed

94 enrolled

GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT04389632 2026-05-11

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

GastrointestinalGenitourinaryGynecologicHead & NeckThoracic

1,006 enrolled

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms

NCT05581004 2026-05-11

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

450 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms

NCT05903833 2026-05-11

PIERCE

42 enrolled

Phase 1 Active not recruiting

Vulvar Neoplasms

NCT03932409 2026-05-08

FIERCE

45 enrolled

Endometrial Neoplasms

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

30 enrolled

Uterine Cervical Neoplasms

NCT06989112 2026-05-06

DE-01

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT04430699 2026-05-05

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

24 enrolled

Phase 3 Active not recruiting

Vulvar Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

280 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT03740165 2026-05-04

KEYLYNK-001

Phase 3 Completed

1,367 enrolled 29 charts

BreastCNSGastrointestinalGynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03797326 2026-05-04

LEAP-005

Phase 2 Completed

611 enrolled 27 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Biliary Tract Neoplasms, Glioblastoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03914612 2026-05-04

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Phase 3 Active not recruiting

813 enrolled 16 charts 1 FDA

GynecologicSarcoma

Carcinosarcoma, Endometrial Neoplasms

NCT07218003 2026-05-04

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Phase 1 Enrolling by invitation

149 enrolled

BreastGastrointestinalGenitourinaryGynecologicThoracic

Esophageal Squamous Cell Carcinoma, Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT06180733 2026-05-01

PAM-II

12 enrolled

GynecologicLymphoid

Lymphoma, Follicular, Uterine Neoplasms, Endometrial Neoplasms

NCT05156268 2026-04-27

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Phase 2 Completed

26 enrolled

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT06157151 2026-04-23

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

24 enrolled

Uterine Cervical Neoplasms

NCT05208762 2026-04-20

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & NeckThoracic

714 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06270706 2026-04-20

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

124 enrolled

Anus Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT03786081 2026-04-14

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Terminated

214 enrolled

Uterine Cervical Neoplasms

NCT05446298 2026-04-13

PRESERVE-004

58 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06253494 2026-04-09

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

60 enrolled

Endometrial Neoplasms

NCT07262619 2026-04-08

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

160 enrolled

Turcot syndrome, Neoplasm Metastasis, Endometrial Neoplasms

NCT05920798 2026-04-06

FRAPPE

40 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03428802 2026-04-03

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

21 enrolled 9 charts

BreastGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms

NCT07290894 2026-04-02

MITO VULVA-01

80 enrolled